Boston Scientific's Urology/Gynecology Products Featured in Studies at Globa...(oking statements include among other thi...),Health

Date:11/9/2009

oking statements include, among other things, statements regarding product performance, clinical trials and physician education. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-lo
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Boston Scientifics Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
2. Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
3. Boston Medical Center Managing H1N1 Flu Vaccination for its Community with Carefxs New Immunization Management Solution
4. Boston Scientific Announces Results for Third Quarter Ended September 30, 2009
5. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
6. Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex(R) Biliary RX Covered Stents
7. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
8. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
9. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
10. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
11. Boston Scientific Announces Schedule for European Society of Cardiology Congress